Brainstorm Cell Therapeutics Inc. - Common Stock (BCLI)
Frequently Asked Questions About Brainstorm Cell Therapeutics Inc. - Common Stock (BCLI)
Can patients currently access NurOwn therapy?
Currently, access to NurOwn is limited to clinical trial participants, and Brainstorm is working towards making the therapy more widely available pending regulatory approvals and successful trial outcomes.
Has Brainstorm received any regulatory approvals?
As of now, Brainstorm is seeking regulatory approval for NurOwn from the FDA, and the company is actively engaging with regulatory authorities throughout the clinical trial process.
How can investors obtain information about Brainstorm's financial performance?
Investors can obtain information about Brainstorm Cell Therapeutics Inc.'s financial performance by accessing their quarterly and annual reports filed with the Securities and Exchange Commission (SEC) or by visiting the investor relation's section on their corporate website.
How does Brainstorm fund its research and development?
Brainstorm funds its research and development through a combination of private investments, public offerings, collaborations, and grants from organizations that support innovative healthcare solutions.
How does NurOwn work?
NurOwn works by expanding a patient's own mesenchymal stem cells in the laboratory and then inducing those cells to secrete beneficial factors that can promote neuronal survival, reduce inflammation, and repair damaged nerves.
Is Brainstorm Cell Therapeutics Inc. publicly traded?
Yes, Brainstorm Cell Therapeutics Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol BCLI.
What are some recent milestones for Brainstorm?
Recent milestones for Brainstorm include advancements in clinical trial phases for NurOwn, presentations at major scientific conferences, and collaborations that strengthen their research potential in regenerative medicine.
What are the other diseases Brainstorm is targeting besides ALS?
In addition to ALS, Brainstorm is also exploring the use of its cell therapy platform for treating multiple sclerosis, Parkinson's disease, and potential applications in other neurodegenerative disorders.
What are the potential side effects of NurOwn?
As with any medical therapy, NurOwn may have side effects, which are generally mild and can include discomfort at the injection site or transient flu-like symptoms, but full data from clinical trials is necessary for a complete understanding.
What does Brainstorm Cell Therapeutics Inc. do?
Brainstorm Cell Therapeutics Inc. is a biotechnology company that focuses on developing innovative cell therapies for neurodegenerative diseases, particularly its lead product, NurOwn, an autologous stem cell therapy aimed at treating amyotrophic lateral sclerosis (ALS) and other conditions.
What is Brainstorm’s approach to patient and physician engagement?
Brainstorm actively engages with patients and physicians through educational initiatives, support programs, and involvement in clinical studies to ensure that their needs and concerns are integrated into the development process of therapies.
What is NurOwn?
NurOwn is an innovative cell therapy derived from mesenchymal stem cells that are obtained from a patient's own bone marrow. The therapy is designed to produce neuroprotective factors that can improve the condition of patients suffering from neurodegenerative diseases.
What is the current status of NurOwn in clinical trials?
As of the latest updates, NurOwn has undergone multiple clinical trials for ALS and other disorders, with promising results reported in terms of safety and efficacy. The company is focused on advancing the regulatory process and seeking approval from the FDA.
What is the mission of Brainstorm Cell Therapeutics Inc.?
The mission of Brainstorm Cell Therapeutics Inc. is to develop groundbreaking therapies that harness the power of stem cells to improve the lives of patients suffering from debilitating neurodegenerative diseases.
What is the significance of Brainstorm’s Nasdaq listing?
The Nasdaq listing enhances Brainstorm Cell Therapeutics Inc.'s visibility and credibility in the investment community, allowing the company to attract capital and increase its capacity for research and development.
What partnerships or collaborations does Brainstorm have?
Brainstorm has engaged in various collaborations with academic institutions and pharmaceutical companies to enhance its research capabilities and accelerate the development of its therapies, contributing to robust scientific validation.
When was Brainstorm Cell Therapeutics Inc. founded?
Brainstorm Cell Therapeutics Inc. was founded in 2004, with the goal of developing cell-based therapies to address the unmet medical needs of patients with severe neurological conditions.
Where is Brainstorm Cell Therapeutics Inc. located?
Brainstorm Cell Therapeutics Inc. is headquartered in New York City, New York, where it conducts its operations related to research, clinical trials, and corporate governance.
Who are the key members of Brainstorm's management team?
Brainstorm's management team comprises experienced professionals with expertise in biotechnology, finance, and corporate strategy, including CEO Chaim Lebovits and other members with strong backgrounds in clinical development and regulatory affairs.
What is the current price of Brainstorm Cell Therapeutics Inc. - Common Stock?
The current price of Brainstorm Cell Therapeutics Inc. - Common Stock is 1.226
When was Brainstorm Cell Therapeutics Inc. - Common Stock last traded?
The last trade of Brainstorm Cell Therapeutics Inc. - Common Stock was at 10:57 am EDT on April 3rd, 2025
What is the market capitalization of Brainstorm Cell Therapeutics Inc. - Common Stock?
The market capitalization of Brainstorm Cell Therapeutics Inc. - Common Stock is 7.53M
How many shares of Brainstorm Cell Therapeutics Inc. - Common Stock are outstanding?
Brainstorm Cell Therapeutics Inc. - Common Stock has 6.14M shares outstanding.